2024年5月23日 · XDR-TB, an abbreviation for extensively drug-resistant tuberculosis (TB), is a form of TB that is caused by a strain of M. tuberculosis complex that is resistant to rifampicin (and may also be resistant to isoniazid), and that is also resistant to at least one fluoroquinolone (levofloxacin or moxifloxacin) and to at least one other Group A drug ...

Extensively drug-resistant tuberculosis (XDR-TB) is a form of tuberculosis caused by bacteria that are resistant to some of the most effective anti-TB drugs. XDR-TB strains have arisen after the mismanagement of individuals with multidrug-resistant TB (MDR-TB).

xdr-tb是广泛耐药结核病的缩写。 它是一种由结核分枝杆菌复合群菌株引起的结核病，该菌株对利福平耐药（也可能对异烟肼有耐药性），并且对至少一种氟喹诺酮类药物（左氧氟沙星或莫西沙星）和至少一种其他A类药物（贝达喹啉或利奈唑胺）耐药。

广泛耐药结核（Extensively drug-resistant tuberculosis，即XDR-TB）是结核病的一种，专指对利福平（rifampicin）和异烟肼（isoniazid）具抗药性（对这些一线治疗结核药物具有抗药性的结核称作“多药抗药性结核”——MDR-TB），且对全部喹诺酮（quinolone）类药物以及至少对 ...

2021年1月27日 · The definition of extensively drug-resistant tuberculosis (XDR-TB) has been revised by the World Health Organization (WHO)’s Global TB Programme, who have also defined pre-XDR-TB for the first time, highlighting the seriousness of these forms of TB.

Multidrug-resistant TB disease (MDR TB) is caused by germs that are resistant to two or more of the main TB medicines: isoniazid and rifampin. Two more serious forms of MDR TB are called pre-extensively drug-resistant TB (pre-XDR TB) and extensively drug-resistant TB (XDR TB).

2．xdr-tb： 是指结核病患者感染的结核分枝杆菌体外药敏试验证实除至少同时对异烟肼和利福平耐药外，还对任何喹诺酮类药物耐药，以及3种二线注射类药物（卷曲霉素、卡那霉素和阿米卡星）中的至少1种耐药的结核病。

2025年1月6日 · Extensively drug-resistant TB (XDR TB) is a rare type of MDR TB caused by TB bacteria that are resistant to: Isoniazid and rifampin, a fluoroquinolone, and a second-line injectable (amikacin, capreomycin, and kanamycin) or

This chapter provides guidance on the strategies for the treatment of multidrug- and extensively drug-resistant TB (M/XDR-TB), with emphasis on regimen design. The treatment of mono- and poly-drug-resistant TB is addressed in Chapter 6.

结核病作为全球疾病十大死因之一，是重大的公共卫生问题，其中耐药结核病 (drug-resistant tuberculosis, DR-TB)是结核病控制面临的重大挑战。 WHO发布的《2020年全球结核病报告》显示，2019年全球估算新发结核病患者996万例，估算新发耐多药结核病 (multidrug-resistant tuberculosis，MDR-TB)/利福平耐药结核病 (rifampicin resistant tuberculosis，RRTB)患者约46.5万例，登记报告MDR-TB/RRTB患者206 030例，占估算发病总数的44% [1]。